Another study shows that the adoptive transfer of MDSCs to HCC-bearing mice not only promotes HCC progression, partially by activating tumor-associated fibroblasts via IL-6/fibroblast growth factor 1 (FGF1) signaling, but also induces resistance to sorafenib treatment [91]. Here, IL6 is linked to neoplasm.